Abstract：Objective To investigate the infections occurring in the induction period of childhood acute lymphoblastic leukemia (ALL), the pathogens of the infections, and drug resistance of isolated strains. Methods A retrospective analysis was performed for the clinical data of 130 children with newly-diagnosed childhood ALL. Infections occurring during the induction chemotherapy, pathogenic strains, and drug-resistance spectrum were analyzed. Results The incidence rate of clinical infection and/or microbial infection reached 76.2%. The lungs were the most common infection site (46.2%). The children with severe infection accounted for 52.3%, among whom 60 had pulmonary infection and/or 21 had sepsis. A total of 50 pathogenic strains were detected, which consisted of 29 bacterial strains and 21 fungal strains. Of all the children, 28.5% experienced infections caused by at least one microbe. Among the 29 bacterial strains, there were 19 (65.5%) Gram-negative bacteria and 10 (34.5%) Gram-positive bacteria. The most common Gram-negative bacteria were Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa, which were 100% sensitive to imipenem. The most common Gram-positive bacterium was Streptococcus viridans, which was 100% sensitive to vancomycin. The infections caused by fungi accounted for 16.2%, with Candida albicans as the most common fungus. Compared with those with non-severe infections, the children with severe infections had a significantly shorter time to the occurrence of agranulocytosis, a significantly longer duration of agranulocytosis,significantly higher incidence of fever and C-reactive protein (CRP) level, and a significantly longer length of hospital stay (P < 0.05). Conclusions Pulmonary infections are common in the induction period of childhood ALL. Gramnegative bacteria are the most common pathogenic bacteria. Severe infections can be controlled by carbapenems combined with vancomycin and antifungal agents.
CHEN Zai-Sheng,ZHENG Ling,CHEN Yi-Qiao et al. Pathogens of infections in the induction period of childhood acute lymphoblastic leukemia and drug resistance of isolated strains[J]. CJCP, 2017, 19(2): 176-181.
Fisher BT,Sammons JS,Li Y,et al.Variation in risk of hospital-onset clostridium difficile infection across beta-lactam antibiotics in children with new-onset acute lymphoblastic leukemia[J].J Pediatric Infect Dis Soc,2014,3(4):329-335.
[2]
Badiei Z,Khalesi M,Alami MH,et al.Risk factors associated with life-threatening infections in children with febrile neutropenia:a data mining approach[J].J Pediatr Hematol Oncol,2011,33(1):e9-e12.
Khurana M,Lee B,Feusner JH.Fever at diagnosis of pediatric acute lymphoblastic leukemia:are antibiotics really necessary[J].J Pediatr Hematol Oncol,2015,37(7):498-501.
[6]
O'Connor D,Bate J,Wade R,et al.Infection-related mortality in children with acute lymphoblastic leukemia:an analysis of infectious deaths on UKALL2003[J].Blood,2014,124(7):1056-1061.
[7]
Ma X,Urayama K,Chang J,et al.Infection and pediatric acute lymphoblastic leukemia[J].Blood Cells Mol Dis,2009,42(2):117-120.
[8]
Li SD,Chen YB,Li ZG,et al.Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia:a single-center experience with 256 cases in China[J].Chin Med J (Engl),2015,128(4):472-476.
[9]
Afzal S,Ethier MC,Dupuis LL,et al.Risk factors for infectionrelated outcomes during induction therapy for childhood acute lymphoblastic leukemia[J].Pediatr Infect Dis J,2009,28(12):1064-1068.
[10]
Ammann RA,Bodmer N,Hirt A,et al.Predicting adverse events in children with fever and chemotherapy-induced neutropenia:the prospective multicenter SPOG 2003 FN Study[J].J Clin Oncol,2010,28(12):2008-2014.
Hatzistilianou M,Rekliti A,Athanassiadou F,et al.Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia[J].Inflamm Res,2010,59(5):339-347.
[13]
Christ-Crain M,Jaccard-Stolz D,Bingisser R,et al.Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:cluster-randomised,singleblinded intervention trial[J].Lancet,2004,363(9409):600-607.
Bothra M,Seth R,Kapil A,et al.Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients[J].Indian J Pediatr,2013,80(4):297-302.
[16]
Pokala HR,Leonard D,Cox J,et al.Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia[J].Pediatr Blood Cancer,2014,61(2):276-280.
